You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Optimizing membrane repair for the treatment of Duchenne muscular dystrophy
SBC: MYOFINITY BIOSCIENCES INC Topic: NIAMSPROJECT ABSTRACT The long term goal of this project is to optimize a protein therapeutic for Duchenne muscular dystrophyDMDand potentially other muscle diseasesthat will enhance the repair capacity of muscle cell membranes that are compromised by mutations in the dystrophin dystroglycan complexMutations in the dystrophin dystroglycan complex result in Duchenne muscular dystrophyMyos Incis developi ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based
SBC: KLEIN BUENDEL, INC. Topic: 102Project Summary While studies support the efficacy of comprehensiveschool wide interventions in reducing bullyingthese types of programs can require significant time and financial resources for implementationresulting in barriers to providing school based bullying preventionespecially in low income and rural communitiesAdditionallyalthough training bystanders to act asdefenderson behalf of targets ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Gene Therapy to Prevent Esophageal Cancer Associated with Aldehyde Dehydrogenase Deficiency
SBC: LEXEO Therapeutics LLC Topic: 400AbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using in vivo gene therapy technologies to treat disorders of unmet medical needLEXEO is developing an in vivo gene therapy strategy as a preventative therapy to protect individuals with aldehyde dehydrogenaseALDHdeficiency from the high risk for esophageal cancerAs the next step in the development paththe goal of this ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Epitaxial GaN on flexible metal tapes for low-cost transistor devices
SBC: IBEAM MATERIALS, INC. Topic: 1GaN-based devices are the basis of a variety of modern electronics applications, especially in optoelectronics and high-frequency / high-power electronics. These devices are based on epitaxial films grown on single-crystal wafers. The single-crystal wafer substrates are limiting because of their size, expense, mechanical properties and availability. If one could make GaN-based devices over large a ...
STTR Phase I 2013 Department of EnergyARPA-E -
Improving liver lesion biopsy in the CT suite through fusion with PET images
SBC: KITWARE INC Topic: NCIDESCRIPTION (provided by applicant): The broad objective of this proposal is to improve the clinical effectiveness of liver lesion biopsy by fusing respiratory-compensated PET with CT images in the CT suite. On CT imaging alone, localization of liver lesions can potentially be challenging, particularly in selected cases where differentiation of the tumor from adjacent liver parenchyma may be diffi ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Nanoparticle scavengers for medical countermeasures against mycotoxin
SBC: Luna Innovations Incorporated Topic: NIGMSDESCRIPTION (provided by applicant): Mycotoxin is naturally occurring and is a toxic small molecule produced by fungi. These fungal toxins are representative of a large number of lipophilic agents that pose significant acute and chronic dangers to militarycombatants as potential warfare agents. There are many examples of mycotoxins, some more acutely potent than others. Mycotoxin is classified as ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Web-Based Infrastructure for Comparison and Validation of Image Computing Methods
SBC: KITWARE INC Topic: NIBIBDESCRIPTION (provided by applicant): Validation of computing algorithms has been a challenging topic over the last few years. In fact, several international workshops in the medical imaging field started to involve the community through grand challenges . A grand challenge involves selecting driving biological/scientific problem and asking experts to submit their best results and methods to solve ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Fluorescence Image-Guided Near Infrared (NIR) Photodynamic Therapy (PDT) Agent
SBC: PHOTOLITEC LLC Topic: NCIDESCRIPTION (provided by applicant): Photolitec's patented technology is focused on developing improved agents for tumor- imaging, image-guided surgery and/or photodynamic therapy (PDT). The proposed STTR proposal includes fluorescence-image guided PDT, aSee and Treat approach. The fluorescence imaging compound with long wavelength absorption near 800 nm should be extremely useful for image ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Live-Cell Fluorescence Lifetime FRET Assays for HTS
SBC: Fluorescence Innovations, Inc. Topic: NIDADESCRIPTION (provided by applicant): This project will establish proof-of-concept for a powerful and versatile implementation of live-cell assays in a true high-throughput screening (HTS) format for small-molecule drug discovery. The technological basis isfluorescence lifetime (FLT) readout of FRET between fluorescent fusion proteins. Lifetime measurement is needed in HTS to overcome the low preci ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Topical Nanoparticles for CNV
SBC: NANOTRANS TECHNOLOGIES, INC. Topic: NEIDESCRIPTION (provided by applicant): Age Related Macular Degeneration (AMD) is the leading cause of blindness in adults over 50 years. Choroidal neovascularization (CNV), the pathologic creation of new blood vessels in the choroid layer of the eye, is a principal cause of blindness due to AMD. Current therapeutic management of AMD is far from optimal and requires repeated injections in the vitreou ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health